Northwell Health was one of many who conducted a pioneering clinical trial to treat rheumatoid arthritis through a chip implanted on the vagus nerve. The first technology of its kind yielded ...

The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA). The ...

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced that the U.S. Food and Drug ...

The device stimulates the vagus nerve, signaling the body to tamp down the inflammation that contributes to the disease. An example of the vagus nerve stimulation implant at the Northwell Center for ...

NEW HYDE PARK, N.Y. & VALENCIA, Calif.--(BUSINESS WIRE)--Northwell Health and SetPoint Medical today announced that Northwell is the first health system to provide the recent U.S. Food and Drug ...

SetPoint Medical has secured $140m through private financing, earmarked for the commercial rollout of the SetPoint System, a neuroimmune modulation therapy designed for patients with ...

The US Food and Drug Administration (FDA) recently approved a medical device that could bring new hope to patients suffering from rheumatoid arthritis (RA), a chronic autoimmune condition often ...

In less than two weeks, Setpoint Medical Inc. mastered the power serve with the first approval of a neuroimmune modulation device to manage rheumatoid arthritis, followed by a $25 million second ...

SetPoint Medical, a Valencia-based company dedicated to developing therapies for people living with chronic autoimmune diseases, raised $140 million in private financing that includes $25 million in ...

SetPoint System offers the first clinically-proven neuromodulation treatment option for rheumatoid arthritis (RA) SetPoint Medical, a company dedicated to developing therapies for people living with ...